We are live on ! Find out more
BVS icon

Bioventus

157 hedge funds and large institutions have $509M invested in Bioventus in 2026 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 75 increasing their positions, 38 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more call options, than puts

Call options by funds: $2.21M | Put options by funds: $491K

97% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 38

13% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 23

9% more capital invested

Capital invested by funds: $466M → $509M (+$43M)

3.69% more ownership

Funds ownership: 75.79%79.48% (+3.7%)

0% more funds holding

Funds holding: 157157 (0)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

Holders
157
Holders Change
Holders Change %
0%
% of All Funds
1.89%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
26
Increased
75
Reduced
38
Closed
23
Calls
$2.21M
Puts
$491K
Net Calls
+$1.72M
Net Calls Change
+$124K

BVS Hedge Fund Activity: Q2 2026 in Review

157 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Bioventus (BVS) for Q2 2026, worth a combined $509M — up 9.2% from $466M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new BVS positions and 23 closed out — a net gain of 3 holders — while 75 added to existing stakes and 38 trimmed.

The largest buyer was American Century Companies, adding an estimated $7M. The largest seller was Essex Investment Management, exiting entirely with an estimated $5.51M sold.

  • 157 institutional investors held Bioventus (BVS) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $509M of Bioventus stock for Q2 2026, up 9.2% quarter-over-quarter.
  • 26 funds opened new Bioventus positions in Q2 2026 and 23 closed out, a net change of +3 holders.
  • The largest Bioventus buyer in Q2 2026 was American Century Companies, an estimated $7M added.
  • The largest Bioventus seller in Q2 2026 was Essex Investment Management, an estimated $5.51M sold.

Based on aggregated 13F filings for Q2 2026.